Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
BETHLEHEM, Pa., Feb. 02, 2018 -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced the appointment of Dr. Aradhana Sarin, as a member of the Company's Board of Directors. Dr. Sarin will serve as a Class II Director with an initial term expiring at the Company’s 2020 Annual Meeting of Stockholders. She will also serve on the Audit Committee and Nominating and Corporate Governance Committee of the Board.
“As OraSure continues to grow and execute against its strategic priorities, we welcome the addition of Aradhana to our Board of Directors,” said Stephen S. Tang, Ph.D., Chairman of the Board. “Aradhana’s many years of experience in the healthcare industry, first as a medical doctor and then as an investment banker, will add a valuable new perspective and skill set to our Board. With her long and successful track record in leading the healthcare practice of a major investment bank, Aradhana brings not only executive leadership to the Board but also extensive knowledge in business development and strategic matters, both of which will be critical as the Company pursues its future growth strategy.”
Dr. Sarin, 43, currently serves as Senior Vice President, Head of Corporate Business Development & Strategy for Alexion Pharmaceuticals, a global biopharmaceutical company that is serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Dr. Sarin also serves as Co-Chair of the Executive Management Committee overseeing Science and Innovation at Alexion.
Dr. Sarin brings over 20 years of professional experience at global financial institutions. She has extensive knowledge of global healthcare systems, and has closed over 100 M&A, equity and debt financing transactions. Prior to Alexion, Dr. Sarin was at Citi Global Banking, where she served as the Managing Director of Healthcare Corporate & Investment Banking, focusing on clients in the diagnostics, life sciences and biopharmaceutical sectors. Prior to joining Citi, Dr. Sarin served as Managing Director of Healthcare Investment Banking at UBS, where she led a number of complex M&A deals. Prior to this, Dr. Sarin worked at JP Morgan in the M&A Advisory and Healthcare groups focusing on transaction execution. Before her banking career, Dr. Sarin spent two years as a medical resident doctor practicing in both India and Africa. Dr. Sarin has a strong orientation for science, an excellent understanding of the entire healthcare sector, extensive relationships, and deep transactional experience. Dr. Sarin received her MBA from Stanford Business School and obtained her medical training from the University of Delhi.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit www.orasure.com.
Company contact: Ronald H. Spair Chief Financial Officer 610-882-1820 [email protected] Shauna White Corporate Marketing Manager 484-353-1575 [email protected]
